Harrison.ai, a leading global healthtech company and developer of artificial intelligence (AI)-powered medical diagnostic support and workflow solutions, has announced the accelerated expansion of its operations into the United States, a move supported by $112 million of Series C funding.
The funding will also fuel the company’s product roadmap and continued growth in the UK, EMEA and APAC. The round is one of the largest capital raises in the medical AI space over the past twelve months.
The round was co-led by Aware Super, ECP and existing investor, Horizons Ventures. New investors, such as Australia’s National Reconstruction Fund Corporation (NRFC), Ord Minnett and Wollemi Capital Group also participated, along with existing investors including Blackbird Ventures and Alpha JWC Ventures. Harrison.ai’s total capital raised to date exceeds US$240 million.
Harrison’s technology in radiology and pathology assists clinicians with identifying signs of cancer and other critical illnesses earlier, improving treatment decisions and patient outcomes. It uses AI to analyse CT scans, X-rays, and pathology slides, supporting clinicians in detecting and diagnosing medical conditions faster and more accurately.
Over 1,000 healthcare facilities worldwide support the care of more than six million patients each year with Harrison.ai solutions. Its radiology solution (Annalise.ai) is available to 1 in 2 radiologists in Australia, and processes scans for more than 45 Trusts and over 131 public hospitals in the United Kingdom, including 35% of chest X-ray volume in England. It also powers all CT Brain scans across public accident and emergency (A&E) systems in Hong Kong and was recently selected by the Danish public healthcare system to help clinicians deliver better outcomes.
Further accelerating its global commercialisation efforts, Harrison.ai is establishing a North American presence in Boston. The company will focus on building its US operations and growing the Harrison.ai customer base. The company has already received 12 FDA clearances, and one of its CT Brain algorithms has FDA Breakthrough Device Designation and Medicare reimbursement through the New Technology Add-on Payment (NTAP).
